Cetuximab is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.
It is a chimeric monoclonal antibody that binds and inhibits the epidermal growth factor receptor (EGFR).
It is administered through intravenous infusion every week.
In 2016, it sold €350 million in Europe.
Labs that test for drug level: